Page 52 - 南京医科大学学报自然科学版
P. 52

第41卷第12期
               ·1758 ·                           南 京    医 科 大 学 学         报                        2021年12月


                  鼠疫的临床治疗通常以链霉素联用其他类型                           [6] 吴智远,焦      磊,徐    兵,等. 抗鼠疫耶尔森菌 F1 抗原
              抗生素为主。在预防鼠疫方面,灭活疫苗已投入临                                 单克隆抗体对小鼠的被动免疫保护作用[J]. 微生物学
              床应用近百年,尽管近年来已研制出亚单位疫苗及                                 免疫学进展,2018,46(1):7-13
              DNA 疫苗,但有待临床试验验证其安全性及有效                           [7] 林    芸,阎锡蕴. 人源化抗体研究历程及发展趋势[J].
                                                                     生物工程学报,2004,20(1):1-5
              性。近年来发现多种耐药鼠疫杆菌,单纯的药物治
                                                                [8] AMIRI M M,BAHADORI T,SOLTANTOYEH T,et al.
              疗效果不明显      [12-14] ,随着恐怖主义势力抬头,耐药鼠
                                                                     Development of a novel inhibitory chimeric anti ⁃ HER2
              疫杆菌被应用于生化武器研发,高效鼠疫治疗方案                                 monoclonal antibody[J]. Iran J Immunol,2019,16(1):
              的开发被提上日程。本研究制备的抗 F1 嵌合抗体                               26-42
              可以与F1抗原特异性结合,可有效应用于鼠疫检测                           [9] VERHOEYEN M E,SAUNDERS J A,PRICE M R,et al.
              与治疗。在后续研究中,需进行动物实验及临床试                                 Construction of a reshaped HMFG1 antibody and compari⁃
              验,分析其安全性及保护效率,为人源化中和抗体                                 son of its fine specificity with that of the parent mouse an⁃
              应用于鼠疫临床救治奠定基础。                                         tibody[J]. Immunology,1993,78(3):364-370
                                                                [10] WALTHER C G,WHITFIELD R,JAMES D C. Impor⁃
             [参考文献]
                                                                     tance of interaction between integrin and actin cytoskele⁃
             [1] BRAMANTI B,STENSETH N C,WALLØE L. Plague:a          ton in suspension adaptation of CHO cells[J]. Appl Bio⁃
                   disease which changed the path of human civilization[J].  chem Biotechnol,2016,178(7):1286-1302
                   Adv Exp Med Biol,2016,918:1-26               [11] CHAHAR D S,RAVINDRAN S,PISAL S S. Monoclonal
             [2] BRUBAKER R R. physiology of yersinia pestis[J]. Adv⁃  antibody purification and its progression to commercial
                   Exp Med Biol,2016,918:79-99                       scale[J]. Biologicals,2020,63:1-13
             [3] RAI R,DAS B,CHOUDHARY N,et al. MAP of F1 and V  [12] CABANEL N,BOUCHIER C,RAJERISON M,et al. Plas⁃
                   antigens from Yersinia pestis astride innate and adaptive  mid⁃mediated doxycycline resistance in a Yersinia pestis
                   immune response[J]. Microb Pathog,2015,87:13-20   strain isolated from a rat[J]. Int J Antimicrob Agents,
             [4] GAHLOT D K,IFILL G,MACINTYRE S. Optimised het⁃      2018,51(2):249-254
                   erologous expression and functional analysis of the Yersin⁃  [13] PLATONOV M E,SVETOCH T E,EVSEEVA V V,et al.
                   ia pestis F1 ⁃ capsular antigen regulator Caf1R[J]. Int J  Polymorphism of the cysteine protease YopT from Yersin⁃
                   Mol Sci,2021,22(18):9805                          ia pestis[J]. Protein Pept Lett,2016,23(4):379-385
             [5] CHATTERJEE S,LESNIAK W G,GABRIELSON M,et       [14] DAI R,HE J,ZHA X,et al. A novel mechanism of strepto⁃
                   al. A humanized antibody for imaging immune checkpoint  mycin resistance in Yersinia pestis:mutation in the rpsL⁃
                   ligand PD⁃L1 expression in tumors[J]. Oncotarget,2016,  gene[J]. PLoS Negl Trop Dis,2021,15(4):e0009324
                   7(9):10215-10227                                                       [收稿日期] 2021-06-03



                                                                                                 
















                              欢迎关注我刊微博、微信公众号!







                              
   47   48   49   50   51   52   53   54   55   56   57